CD73 on cancer-associated fibroblasts enhanced by the A<sub>2B</sub>-mediated feedforward circuit enforces an immune checkpoint.

Yu, Miao; Guo, Gang; Huang, Lei; Deng, Libin; Chang, Chang-Sheng; Achyut, Bhagelu R; Canning, Madison; Xu, Ningchun et al. · Nat Commun · 2020

basic_science · Level V

Where this comes from

Abstract

CD73, an ecto-5'-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A<sub>2A</sub> receptor. Elevated CD73 levels in tumor tissues correlate with poor clinical outcomes. However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified. Here, we demonstrate that cancer-associated fibroblasts (CAFs) constitute the prominent CD73<sup>hi</sup> population in human colorectal cancers (CRCs) and two CD73<sup>-</sup> murine tumor models, including a modified CRC. Clinically, high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis. Mechanistically, CAF-CD73 expression is enhanced via an ADO-A<sub>2B</sub> receptor-mediated feedforward circuit triggered by tumor cell death, which enforces the CD73-checkpoint. Simultaneous inhibition of A<sub>2A</sub> and A<sub>2B</sub> pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors. Therefore, the strategic and effective targeting of both the A<sub>2B</sub>-mediated ADO-CAF-CD73 feedforward circuit and A<sub>2A</sub>-mediated immune suppression is crucial for improving therapeutic outcomes.

Medical subject headings